APA (7th ed.) Citation

V, W., M, L., G, D., W, F., R, M., S, H., . . . P, V. (2011). Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. Cancer management and research, 3, 157. https://doi.org/10.2147/CMR.S19341

Chicago Style (17th ed.) Citation

V, Wacheck, et al. "Dose Study of the Multikinase Inhibitor, LY2457546, in Patients with Relapsed Acute Myeloid Leukemia to Assess Safety, Pharmacokinetics, and Pharmacodynamics." Cancer Management and Research 3 (2011): 157. https://doi.org/10.2147/CMR.S19341.

MLA (9th ed.) Citation

V, Wacheck, et al. "Dose Study of the Multikinase Inhibitor, LY2457546, in Patients with Relapsed Acute Myeloid Leukemia to Assess Safety, Pharmacokinetics, and Pharmacodynamics." Cancer Management and Research, vol. 3, 2011, p. 157, https://doi.org/10.2147/CMR.S19341.